Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

In vitro expansion of alloantigen-specific regulatory T cells and their use in prevention of allograft rejection.

Nouzé C, Pasquet L, van Meerwijk JP.

Methods Mol Biol. 2011;707:187-96. doi: 10.1007/978-1-61737-979-6_12.

PMID:
21287336
2.

Immobilized cytokines as biomaterials for manufacturing immune cell based vaccines.

Leclerc C, Brose C, Nouzé C, Leonard F, Majlessi L, Becker S, von Briesen H, Lo-Man R.

J Biomed Mater Res A. 2008 Sep 15;86(4):1033-40.

PMID:
18067172
3.

Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system.

Berraondo P, Nouzé C, Préville X, Ladant D, Leclerc C.

Cancer Res. 2007 Sep 15;67(18):8847-55.

4.

Inhibition of phagosome maturation by mycobacteria does not interfere with presentation of mycobacterial antigens by MHC molecules.

Majlessi L, Combaluzier B, Albrecht I, Garcia JE, Nouze C, Pieters J, Leclerc C.

J Immunol. 2007 Aug 1;179(3):1825-33. Erratum in: J Immunol. 2007 Oct 15;179(8):5604.

5.

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.

Hervas-Stubbs S, Majlessi L, Simsova M, Morova J, Rojas MJ, Nouzé C, Brodin P, Sebo P, Leclerc C.

Infect Immun. 2006 Jun;74(6):3396-407.

6.

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.

Majlessi L, Simsova M, Jarvis Z, Brodin P, Rojas MJ, Bauche C, Nouzé C, Ladant D, Cole ST, Sebo P, Leclerc C.

Infect Immun. 2006 Apr;74(4):2128-37.

Supplemental Content

Support Center